Loading…
Silexion Therapeutics Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in SLXN.
▼ -100.0% over 5Y.
today you would have $0.18▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $19.20 | $301.50 | $1,627.50 | $1,510.50 | |
| P/B | — | 2.3x | — | — | — |
| EPS | -$89.60 | -$3,949.40 | -$818.48 | -$532.46 | |
| ROE | — | -457.63% | — | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| EDVAEndovia Health Sciences, Inc. | $0.31 | — | — | — | — | $1.99M |
| IMCCIM Cannabis Corp. | $3.41 | — | — | — | — | $2.06M |
| SHPHShuttle Pharmaceuticals Holdings, Inc. | $3.54 | 39.3x | 0.6x | — | -326.36% | $2.07M |
| AKANAkanda Corp | $3.89 |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| $2.1M |
| DCOYDecoy Therapeutics Inc. | $2.90 | 0.0x | 0.4x | — | -827.77% | $1.9M |
| MNDRMobile-health Network Solutions | $1.55 | — | 0.1x | — | -47.59% | $1.85M |